Duke logo

DKK1 for Gastric Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drug (DKN-01) is safe by itself and if the study drug may be taken with paclitaxel or pembrolizumab.

What is the Condition Being Studied?

Gastric cancer

Who Can Participate in the Study?

Adults who:
- Have histologically confirmed recurrent or metastatic esophageal or GEJ squamous cell or adenocarcinoma

Age Group
Adults

What is Involved?

If you choose to join this study you will:
- Be put into Parts A-F or monotherapy of this study
-- For parts A-E, you will be given DKN-01 through your vein on Day 1 and Day 15, and paclitaxel on Day 1, 8, 15 and 22 of each 28 day cycle
-- If you are put in Arm F, you will be given DKN-01 through your vein on Day 1, and 15, and pembrolizumab on Day 1 of each 21 day cycle
-- If you are put in the monotherapy sub-study, you will only get DKN-01 on Day 1 and 15 of each 28 Day cycle

Study Details

Full Title
DEK-DKK1-P102: A Multi Part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination with Paclitaxel or Pembrolizumab in Patients with Relapsed or Refractory Esophagogastric Malignancies
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00049984
NCT:NCT02013154
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698